Skip to content

Advertisement

  • Erratum
  • Open Access

Erratum to: Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer

  • 1, 2,
  • 1, 2,
  • 1,
  • 3, 4,
  • 5,
  • 6,
  • 6, 7,
  • 6, 7, 8 and
  • 1, 9Email author
Breast Cancer Research201214:404

https://doi.org/10.1186/bcr3370

  • Received: 12 December 2012
  • Accepted: 13 December 2012
  • Published:

The original article was published in Breast Cancer Research 2012 14:R108

Correction

Following publication of our article [1], we noticed two errors in Figure 3. Panel 3C, Con H3K4me2 was an erroneous duplication of panel 3D, Con H3K4me2 and the incorrect image was included for panel 3D, Con H3K9Ac. The results and conclusions are unaffected. The correct figure is given here as Figure 1.
Figure 1
Figure 1

Pargyline promotes inhibitory epigenetic modifications. (A) MCF-7-PELP1 cells and (B) MCF-7-HER2 cells were treated with pargyline (3 mM), and chromatin immunoprecipitation analysis was performed using H3K4me2-specific, H3K9me2-specific or H3K9ac-specific antibodies and the status of epigenetic modifications was analyzed using real-time PCR with the estrogen receptor target gene GREB1C proximal promoter-specific primers (B). Immunohistochemistry analysis of indicated epigenetic marks was done on (C) MCF-7 and (D) MCF-7-PELP1 xenografts that were treated with or without pargyline. Representative images are shown. Quantitation of staining performed as described in Materials and methods. ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05. PAR, pargyline; PELP1, proline glutamic acid and leucine-rich protein 1.

Notes

Declarations

Authors’ Affiliations

(1)
Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX 78229, USA
(2)
Department of Cell and Structural Biology, University of Texas Health Science Center, San Antonio, TX 78229, USA
(3)
Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 13 Taishogun Nishitakatsukasa-Cho, Kita-ku Kyoto, 403-8334, Japan
(4)
PRESTO, Japan Science and Technology Agency, 4-1-8 Honcho Kawaguchi, Saitama 332-0012, Japan
(5)
Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya Aichi, 467-8673, Japan
(6)
Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 78030, USA
(7)
Center for RNA Interference and Non-coding RNA, University of Texas MD Anderson Cancer Center, Houston, TX 78030, USA
(8)
Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, 78030, USA
(9)
Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, TX 78229, USA

References

  1. Cortez V, Mann M, Tekmal S, Suzuki T, Miyata N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Vadlamudi RK: Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res. 2012, 14: R108-10.1186/bcr3229.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© BioMed Central Ltd 2012

Advertisement